Panobinostat: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Panobinostat. Educational only — not medical advice.
Labeled uses
FARYDAK, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. This indication is approved under accelerated approval based on progression free survival [see Clinical Studies (14.1 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Source: FDA labeling via NIH DailyMed (set 1b97bd3a…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.